Teva Pharma Begins Commercial Launch Of Quetiapine Fumarate Tablets

Teva, Alexa Announce Exclusive U.S. License And Supply Deal For ADASUVE

Teva First Quarter Results Top Estimates

Teva Q1 Profit Down - Quick Facts

Teva Pharmaceutical Industries Q1 13 Earnings Conference Call At 8:00 AM ET

Trade TEVA now with

3/28/2012 8:05 AM ET

Teva Pharmaceutical Industries Ltd. (TEVA: Quote) said it started commercial launch of Quetiapine Fumarate Tablets, the company's generic version of AstraZeneca's (AZN, AZN.L) schizophrenia treatment, Seroquel Tablets.

The brand product had annual sales of approximately $4.6 billion in the United States, based on IMS sales data.

Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 69 Articles

Editors Pick

BoJ Keeps Easing Plan Intact; Upgrades Economic View

The Bank of Japan on Wednesday decided to keep its ultra-loose monetary policy unchanged, as expected, suggesting that the bank is moving cautiously amid concerns over the recent turmoil in the bond market. The policy board said the bank will conduct money market operations so that the monetary base will increase at an annual pace of about JPY 60-70 trillion.

Australia Consumer Morale Falls Sharply On Budget

Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012.

NetApp Profit Tops Estimates; Boosts Buyback; Initiates Dividend

Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.